Mikaela Sjöstrand

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 14 papers. Top paper: “Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes”.

Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes

JAMA(2020)10.1001/jama.2020.1906

N/A

6.7DataRank · unranked

539 citations

Subodh Verma, Kieran F. Docherty, Silvio E. Inzucchi, Inder S. Anand, Jan Bělohlávek +34 more

Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan

JACC Heart Failure(2020)10.1016/j.jchf.2020.04.008

N/A

5.0DataRank · unranked

142 citations

Pardeep S. Jhund, Brian Claggett, Pooja Dewan, Lars Køber, Mikhail Kosiborod +11 more

Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF

Circulation(2022)10.1161/circulationaha.121.058910

N/A

4.7DataRank · unranked

131 citations

Kieran F. Docherty, Hiddo J.L. Heerspink, Rudolf A. de Boer, Kevin Damman, Silvio E. Inzucchi +16 more

Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF

Diabetes Care(2020)10.2337/dc20-1675

N/A

2.7DataRank · unranked

76 citations

Kieran F. Docherty, Lars Køber, Mikhail Kosiborod, Felipe A. Martínez, Piotr Ponikowski +16 more

Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF

Circulation(2021)10.1161/circulationaha.121.053659

N/A

2.5DataRank · unranked

60 citations

Piotr Ponikowski, Kieran F. Docherty, Samvel B. Gasparyan, Michael Böhm, Chern‐En Chiang +16 more

Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA‐HF

European Journal of Heart Failure(2020)10.1002/ejhf.2083

N/A

1.7DataRank · unranked

48 citations

Kieran F. Docherty, Olof Bengtsson, Rudolf A. de Boer, Akshay S. Desai, Jarosław Dróżdż +19 more

Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score

JACC Heart Failure(2022)10.1016/j.jchf.2022.03.009

N/A

1.4DataRank · unranked

29 citations

Pooja Dewan, Ersilia M. DeFilippis, Tor Biering‐Sørensen, Kieran F. Docherty, Pardeep S. Jhund +13 more

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

New England Journal of Medicine(2019)10.1056/nejmoa1911303

N/A

1.3DataRank · unranked

5622 citations

Scott D. Solomon, Silvio E. Inzucchi, Lars Køber, Mikhail N. Kosiborod, Felipe A. Martinez +43 more

Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure

Circulation Heart Failure(2020)10.1161/circheartfailure.120.007879

N/A

1.1DataRank · unranked

27 citations

Pooja Dewan, Pardeep S. Jhund, Silvio E. Inzucchi, Lars Køber, Mikhail Kosiborod +9 more

Relationship of Dapagliflozin With Serum Sodium

JACC Heart Failure(2022)10.1016/j.jchf.2022.01.019

N/A

0.999DataRank · unranked

31 citations

Kieran F. Docherty, Pardeep S. Jhund, Mark C. Petrie, Silvio E. Inzucchi, Lars Køber +12 more

Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction

JACC Heart Failure(2021)10.1016/j.jchf.2021.08.006

N/A

0.900DataRank · unranked

49 citations

Modele O. Ogunniyi, Inder S. Anand, Akshay S. Desai, Mirta Díez, Jonathan G. Howlett +17 more

Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials

The Lancet Diabetes & Endocrinology(2022)10.1016/s2213-8587(21)00295-3

N/A

0.650DataRank · unranked

75 citations

Silvio E Inzucchi, Priya Vart, Niels Jongs, Kieran F Docherty, Pardeep S Jhund +21 more

Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF

JACC Heart Failure(2022)10.1016/j.jchf.2021.09.002

N/A

0.614DataRank · unranked

13 citations

Joanne Simpson, Pardeep S. Jhund, Silvio E. Inzucchi, Lars Køber, Mikhail Kosiborod +10 more

Efficacy and Safety of Sodium–Glucose Co-Transporter 2 Inhibition According to Left Ventricular Ejection Fraction in DAPA-HF

European Journal of Heart Failure(2020)10.1002/ejhf.1867

N/A

0.557DataRank · unranked

40 citations

Scott D. Solomon, Pardeep S. Jhund, Silvio E. Inzucchi, Lars Køber, Mikhail N. Kosiborod +18 more